CD274 and non-small cell lung carcinoma: The biomarker Programmed cell death ligand 1 (PD-L1) is crucial for the selection of patients with e.g., advanced non-small-cell lung cancer (NSCLC) who would respond best to treatment with PD-L1 inhibitors.